The Inner-Workings of Biogen Idec Inc.

$1.95

Add to cart

2 word format

document in English

finance

school essay

published 14/09/2007

review : Completed

level : General public

requested 1 times

Author's resume

Selection criteria

Summary

As noted earlier in this report, Biogen Idec Inc. is an amalgamation of strengths. It has been the merger between IDEC Pharmaceuticals and Biogen. These two pharmaceutical giants have been as one corporation only as of November of 2003; therefore, there have been a very small number of developments within the company. The main focus will be on the merger itself.
The merger was completed on November the 12th establishing a global biotechnology leader under the symbol “BIIB” on the Nasdaq exchange. William H. Rastetter, Ph.D., the company's Executive Chairman, explains, "Based on [their] existing collaboration in oncology, [they] knew that this combination would be an excellent fit, both operationally and culturally.” The Board of Directors of Biogen Idec is consistent of twelve directors, six from each company.

The merger was completed on November the 12th establishing a global biotechnology leader under the symbol 'BIIB' on the Nasdaq exchange
Recent developments in the industry
1. The new technology in development will help rid the human and animal world of a wide array of diseases by fabricating specific antibodies to ward off specific parasites
Ethical issues facing industry
1. Once the final stage of FDA approvals go through, drugs are to be marketed and sold to the public
2. We feel that one of their internal successes is ideal staffing
The above factors has proved to add to the endless potential for growth for Biogen